Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

Aim: To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting. Materials & methods: Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed with Disease Activity Score of 28 joints, European Ligue Against Rheumatism criteria and Simplified Disease Activity Index. Predictors of response were analyzed with binary logistic regression models. Results: Statistically significant decreases in tender and swollen joint counts, laboratory parameters and use of corticosteroids and disease-modifying antirheumatic drugs were found. Disease activity also significantly diminished. Higher Disease Activity Score of 28 joints at baseline was the main predictor of response. No severe adverse events were reported. Conclusion: Certolizumab was effective and well tolerated, particularly in the subpopulation with higher inflammatory burden at baseline.

• Publication year

  2018

• Venue

  Future Science OA

• Publication date

  2018-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4155/fsoa-2017-0149PMID 29682324PMCID 5905631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 21st Century Patient Registries, Ebook Addendum to Registries for Evaluating Patient Outcomes: A User's Guide, 3rd Edition

  2018cited by this paper
• Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial

  2018cited by this paper
• Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial.

  2018cited by this paper
• Treatment with Biologicals in Rheumatoid Arthritis: An Overview

  2017cited by this paper
• Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up

  2017cited by this paper
• Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients

  2017cited by this paper
• Future therapeutic targets in rheumatoid arthritis?

  2017cited by this paper
• Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

  2016cited by this paper
• Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA.

  2016cited by this paper
• Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

  2016cited by this paper
• A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals

  2016cited by this paper
• RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database

  2016cited by this paper
• Summary of product characteristics

  2016cited by this paper
• 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

  2015cited by this paper
• Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

  2015cited by this paper
• Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

  2015cited by this paper
• The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

  2015cited by this paper
• Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies

  2015cited by this paper
• Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register

  2015cited by this paper
• Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study

  2014cited by this paper
• Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol

  2014cited by this paper
• Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

  2014cited by this paper
• Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial

  2014cited by this paper
• Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

  2013cited by this paper
• Look Beyond the Disease Activity Score of 28 Joints (DAS28): Tender Points Influence the DAS28 in Patients with Rheumatoid Arthritis

  2012cited by this paper
• Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

  2012cited by this paper
• Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

  2012cited by this paper
• Certolizumab Pegol

  2012cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2011cited by this paper
• Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial

  2011cited by this paper
• Certolizumab Pegol

  2010cited by this paper
• Rheumatoid arthritis

  2010cited by this paper
• [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis].

  2010cited by this paper
• Registries for Evaluating Patient Outcomes: A User’s Guide

  2010cited by this paper
• The Disease Activity Score and the EULAR response criteria.

  2009cited by this paper
• Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population

  2009cited by this paper
• Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)

  2008cited by this paper
• Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• ¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideracionens clinimétricas y escenarios de simulación

  2008cited by this paper
• [Is the DAS28 Score the Most Adequate Method to Estimate Activity in Rheumatoid Arthritis? Clinimetric Considerations and Simulations Scenarios].

  2008cited by this paper
• Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

  2008cited by this paper
• Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

  2008cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2007cited by this paper
• Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.

  2007cited by this paper
• Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.

  2007cited by this paper
• The British Society for Rheumatology Biologics Register

  2005cited by this paper
• British Society for Rheumatology Biologics Register

  2003cited by this paper
• A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

  2003cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• [Rheumatoid arthritis].

  1983cited by this paper

• Certolizumab pegol na artrite reumatoide severa: Evidência do mundo real em uma coorte argentina: Alcance de objetivos (T2T) em 3 meses e fatores preditivos.

  2024cites this paper
• Certolizumab pegol in severe rheumatoid arthritis: Real-world evidence in an Argentine cohort: Achievement of targets (T2T) at 3 months and predictive factors.

  2024cites this paper
• Certolizumab pegol en artritis reumatoidea severa. Evidencia de la vida real en una cohorte argentina: Logro de objetivos (T2T) a 3 meses y factores predictivos.

  2024cites this paper
• Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol.

  2020cites this paper
• Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis

  2019cites this paper